Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Repare Therapeutics

Company type: Therapeutics

Main focus: Targeted therapies that directly address the genetic alterations associated with selected tumours

Company stage: Clinical

Diseases: Multiple types of cancer

Genome-editing tool: CRISPR, to identify therapeutic targets

Funding stage: IPO (NASDAQ: RPTX)

Location: Montreal, Quebec, Canada.

Website: https://www.reparerx.com

Pipeline: https://www.reparerx.com/pipeline/

Partners: Roche, Bristol Myers Squibb

Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to discovering and developing novel therapeutics. The company uses its genome-wide, CRISPR-enabled, SNIPRx® platform to systematically discover and develop highly-targeted cancer therapies focused on genomic instability, including DNA damage repair.

Tags

HashtagRepare Therapeutics

Company: Repare Therapeutics
close
Search CRISPR Medicine